Comparison of PD-L1 protein expression between primary tumors and metastatic lesions in triple negative breast cancers
Mariya Rozenblit(Yale University), Lajos Pusztai(Yale Cancer Center)
Cited by 126
Related Papers
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)
|Annals of Oncology|2018|774